- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06310733
The Effects of Probiotics, Lactobacillus GG, in the Treatment of Abdominal Pain in Children With Functional Abdominal Pain Disorders
The Effects of Probiotics, Lactobacillus GG, in the Treatment of Abdominal Pain in Children With Functional Abdominal Pain Disorders - A Randomized Controlled Trial
Recurrent or chronic abdominal pain is one of the common gastrointestinal problems in children. While most children do not have organic origins (so called functional abdominal pain disorders; FAPDs), the symptoms can nevertheless be severe enough to impair the patient's quality of life, growth, and development. To help rule out organic disorders and diagnose this condition, some individuals underwent multiple invasive and costly studies.
Generally, the diagnosis of FAPDs is based on clinical symptoms and criteria, it can be divided into irritable bowel syndrome (IBS), abdominal migraine, functional abdominal pain (FAP) and functional dyspepsia (FD). Approximately 14% of children globally, between the ages of 4 and 18, experience functional abdominal pain issues8. In Thailand, the prevalence of FAPDs among adolescents (mean age of 16 years) was 5.3%, functional dyspepsia and irritable bowel syndrome were found to be the most prevalent subtypes.
The pathogenesis of FAPDs is believed to result from disruptions in the microbiota-gut-brain axis, which may happen early in life or throughout. Hence, several studies, specifically in western countries, reported the role of probiotics, specifically Lactobacillus rhamnosus GG (LGG), in modulating abdominal symptoms in children with FAPDs.
It is widely known that the diversity of gut microbiota depends on multiple factors including ethnicity, mode of delivery, dietary and environmental factors. However, the studies on the use of probiotics in pediatric patients with FAPDs have been mainly conducted in western countries. Since there are limited studies on the effectiveness of probiotics in Asian children with FAPDs, the investigators aim to evaluate the effects of probiotics, LGG, in the treatment of children who suffered from FAPDs.
The secondary objectives are to measure daily pain score in children with and without FAPDs, to evaluate and compare the diversity of fecal microbiota in children with FAPDs and those without FAPDs, and to compare the diversity of fecal microbiota between children with FAPDs who took probiotics and those who did not.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Atchariya Chanpong, M.D, Ph.D.
- Phone Number: 6674451250
- Email: atchariya.c@psu.ac.th
Study Locations
-
-
-
Songkhla, Thailand
- Recruiting
- Atchariya Chanpong
-
Contact:
- Atchariya Chanpong, M.D, Ph.D.
- Phone Number: +6674451250
- Email: atchariya.c@psu.ac.th
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Children, aged 6-15 years old, with a diagnosis of IBS or FAP, according to the Rome IV diagnostic criteria. The diagnosis of IBS or FAP was based on a clinical interview performed by pediatric gastroenterologist.
For healthy controls: non-obese children, aged 6-15 years old, without any gastrointestinal symptoms at the time of recruitment.
Exclusion Criteria:
Children who
- had any chronic diseases, including neurobehavioral disorders
- received treatment with antibiotics/probiotics in the previous 2 months
- received medication that affects gastrointestinal motility in the previous 1 week
- had a pain history suggestive of functional dyspepsia/aerophagia/abdominal migraine/functional constipation
- exhibited growth failure
- had gastrointestinal obstructions/stricture
- displayed alarming signs of organic condition
- had previous abdominal surgery
- had abnormal baseline test results as part of their standard work-up (e.g. complete blood counts; erythrocyte sedimentation rate; liver-pancreas-kidney function tests; stool examination for occult blood, ova, and parasites; fecal calprotectin; urinalysis; abdominal ultrasound; 13C-urea breath test; gastric emptying study, if any)
- had family history of peptic ulcer disease or inflammatory bowel disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LGG (ATCC 53103)
A suspension of freeze-dried LGG ATCC53103 in excipients in an aqueous solution supplied in a 10-mL dark bottle with a delivery cap.
|
Participants will take 10 mL of a suspension of freeze-dried LGG ATCC53103 in excipients in an aqueous solution, supplied in a 10-mL dark bottle with a delivery cap.
|
Placebo Comparator: Placebo
An identical aqueous solution in appearance and taste but without LGG.
|
Participants will take 10 mL of an identical aqueous solution in appearance and taste but without LGG, supplied in a 10-mL dark bottle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The response rate of 4 week-probiotics (LGG) on the severity of abdominal pain (number of episodes or the intensity of pain), compared to the conventional treatment, in children who suffered from FAPDs
Time Frame: 12 weeks
|
Faces pain scale (0-6); higher scores mean a worse outcome.
|
12 weeks
|
The response rate of 4 week-probiotics (LGG) on the severity of abdominal pain (number of episodes or the intensity of pain), compared to the conventional treatment, in children who suffered from FAPDs
Time Frame: 12 weeks
|
Visual analog scale (0-10); higher scores mean a worse outcome.
|
12 weeks
|
The response rate of 4 week-probiotics (LGG) on the severity of abdominal pain (number of episodes or the intensity of pain), compared to the conventional treatment, in children who suffered from FAPDs
Time Frame: 12 weeks
|
Daily food and symptom record
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To measure daily pain score in children with and without FAPDs
Time Frame: 12 weeks
|
Faces pain scale (0-6); higher scores mean a worse outcome.
|
12 weeks
|
To measure daily pain score in children with and without FAPDs
Time Frame: 12 weeks
|
Visual analog scale (0-10); higher scores mean a worse outcome.
|
12 weeks
|
To measure daily pain score in children with and without FAPDs
Time Frame: 12 weeks
|
Daily food and symptom record
|
12 weeks
|
To compare the diversity of fecal microbiota in children with FAPDs who took probiotics and those who did not
Time Frame: 4 weeks
|
stool samples for rDNA sequencing before and after 4 weeks of treatment.
|
4 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- REC 66-517-1-1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Functional Abdominal Pain Syndrome
-
Baylor College of MedicineUniversity of WashingtonRecruitingIrritable Bowel Syndrome | Functional Abdominal Pain | Functional Gastrointestinal Disorders | Functional Abdominal Pain Syndrome | Functional Bowel Disorder | Functional Abdominal Pain DisordersUnited States
-
Lawson Health Research InstituteUniversity of Western Ontario, CanadaCompletedFunctional Gastrointestinal Disorders | Functional Abdominal Pain Syndrome | Abdominal Pain (AP)
-
Aarhus University HospitalKarolinska InstitutetRecruitingIrritable Bowel Syndrome | Functional Gastrointestinal Disorders | Functional Abdominal Pain SyndromeDenmark
-
University Medical Center GroningenZonMw: The Netherlands Organisation for Health Research and DevelopmentActive, not recruitingIrritable Bowel Syndrome | Functional Gastrointestinal Disorders | Functional Abdominal Pain SyndromeNetherlands
-
Medical College of WisconsinCompletedDyspepsia | Irritable Bowel Syndrome | Functional Gastrointestinal Disorders | Functional Abdominal Pain SyndromeUnited States
-
Michigan State UniversitySpectrum Health HospitalsWithdrawnFunctional Abdominal Pain SyndromeUnited States
-
University Hospital TuebingenSymbioPharm GmbHUnknownIrritable Bowel Syndrome | Functional Abdominal Pain SyndromeGermany
-
Karolinska InstitutetChild and Adolescent Psychiatry, StockholmRecruitingFunctional Abdominal Pain SyndromeSweden
-
University of Warmia and MazuryNational Science Centre, PolandCompletedFunctional Abdominal Pain SyndromePoland
-
Assiut UniversityUnknownFunctional Abdominal Pain Syndrome
Clinical Trials on LGG
-
Turku University HospitalMassachusetts General Hospital; University of TurkuUnknownBreastfeeding | Premature; Infant, Light-for-datesFinland
-
Washington University School of MedicineTerminatedGastrointestinal NeoplasmsUnited States
-
The University of Texas Health Science Center,...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingAutism Spectrum Disorder | Gastrointestinal SymptomsUnited States
-
University of RoehamptonCompleted
-
Massachusetts General HospitalCompletedHealthy | ElderlyUnited States
-
Chr HansenUniversity of Copenhagen; Herlev HospitalCompleted
-
Örebro University, SwedenChr Hansen; Valio LtdCompleted
-
Federico II UniversityUnknown
-
University of Medicine and Dentistry of New JerseyChr HansenCompletedUpper Respiratory InfectionUnited States
-
Turku University HospitalMead Johnson Nutrition; Academy of FinlandCompletedGut Microbiota | Skin Microbiota | Humoral Immune Responses | Severity of Atopic DermatitisFinland